Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | N/A | -9,114 | N/A | N/A | N/A |
| Depreciation Amortization | N/A | 47 | N/A | N/A | N/A |
| Accounts receivable | N/A | -179 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 1,433 | N/A | N/A | N/A |
| Other Working Capital | N/A | 1,254 | N/A | N/A | N/A |
| Other Operating Activity | 0 | 2,481 | 0 | 0 | 0 |
| Operating Cash Flow | $N/A | $-4,078 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 3,500 | N/A | N/A | N/A |
| PPE Investments | N/A | -25 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | -2 | N/A | N/A | N/A |
| Other Investing Activity | 0 | 47 | 0 | 0 | 0 |
| Investing Cash Flow | $N/A | $3,520 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 4,147 | N/A | N/A | N/A |
| Other Financing Activity | 0 | -44 | 0 | 0 | 0 |
| Financing Cash Flow | $N/A | $4,103 | $N/A | $N/A | $N/A |
| Exchange Rate Effect | N/A | 1 | N/A | N/A | N/A |
| Beginning Cash Position | N/A | 3,543 | N/A | N/A | N/A |
| End Cash Position | N/A | 7,089 | N/A | N/A | N/A |
| Net Cash Flow | $N/A | $3,546 | $N/A | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | N/A | -4,078 | N/A | N/A | N/A |
| Capital Expenditure | N/A | -25 | N/A | N/A | N/A |
| Free Cash Flow | 0 | -4,103 | 0 | 0 | 0 |